G M Petzinger
Overview
Explore the profile of G M Petzinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stefanko D, Shah V, Yamasaki W, Petzinger G, Jakowec M
Neurobiol Dis
. 2017 May;
105:15-32.
PMID: 28502806
Depression, cognitive impairments, and other neuropsychiatric disturbances are common during the prodromal phase of Huntington's disease (HD) well before the onset of classical motor symptoms of this degenerative disorder. The...
2.
Petzinger G, Holschneider D, Fisher B, McEwen S, Kintz N, Halliday M, et al.
Brain Plast
. 2015 Oct;
1(1):29-39.
PMID: 26512345
Animal studies have been instrumental in providing evidence for exercise-induced neuroplasticity of corticostriatal circuits that are profoundly affected in Parkinson's disease. Exercise has been implicated in modulating dopamine and glutamate...
3.
Kintz N, Petzinger G, Akopian G, Ptasnik S, Williams C, Jakowec M, et al.
J Neurosci Res
. 2013 Aug;
91(11):1492-507.
PMID: 23918451
The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic-acid-type glutamate receptor (AMPAR) plays a critical role in modulating experience-dependent neuroplasticity, and alterations in AMPAR expression may underlie synaptic dysfunction and disease pathophysiology. Using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse...
4.
Jakowec M, Donaldson D, Barba J, Petzinger G
Dev Neurosci
. 2001 Aug;
23(2):91-9.
PMID: 11509831
A primary goal of our research is to elucidate the mechanisms involved in neuroplasticity of the basal ganglia in both development and in response to injury. One means to this...
5.
Petzinger G, Quik M, Ivashina E, Jakowec M, Jakubiak M, Di Monte D, et al.
Mov Disord
. 2001 Apr;
16(2):202-7.
PMID: 11295771
Behavioral rating scales for dyskinesia in the non-human primate are frequently used to assess the efficacy of new treatments and to provide a clinical correlative with neurochemical and neuropathological changes....
6.
Kahle P, Jakowec M, Teipel S, Hampel H, Petzinger G, Di Monte D, et al.
Neurology
. 2000 Apr;
54(7):1498-504.
PMID: 10751266
Objective: Comparative study of CSF levels of tau and AD7C-neuronal thread protein (NTP) in patients with AD and control subjects. Background: AD is characterized by neurofibrillary tangles composed of the...
7.
Tolwani R, Jakowec M, Petzinger G, Green S, Waggie K
Lab Anim Sci
. 1999 Sep;
49(4):363-71.
PMID: 10480640
Toxin-induced and genetic experimental models have been invaluable in investigating idiopathic Parkinson's disease (PD). The neurotoxins--reserpine, 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and methamphetamine--have been used to develop parkinsonian models in a...
8.
Jakowec M, Petzinger G, Sastry S, Donaldson D, McCormack A, Langston J
Neurosci Lett
. 1998 Oct;
253(1):13-6.
PMID: 9754793
Alpha-synuclein has recently been shown to be a major constituent of Lewy bodies in Parkinson's disease (PD). This observation led us to investigate the possibility that its detection in the...
9.